| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Not applicable. STn/sialyl-Tn is a carbohydrate tumor-associated antigen, not a drug that targets a specific biological receptor. It is a biomarker that is recognized by monoclonal antibodies (e.g., B72.3) and binds to lectins such as MGL (macrophage galactose-type lectin) on immune cells, modulating immune responses. Its expression is associated with reduced c-Myc and immune modulation.
|
|---|---|
| ln Vitro |
STn expression is associated with cancer progression and poor prognosis. STn expression correlates with axillary node metastasis, ER negativity, and c-erbB-2 expression in breast cancer. It is expressed in approximately 39% of breast cancer cases. STn may have functional significance in the metastatic process, playing a role in cancer development and tumor cell invasiveness, though the mechanisms may be organ-specific.
|
| ln Vivo |
STn/sialyl-Tn is not administered as a therapeutic agent but is used as a biomarker. In breast cancer patients, STn expression seems to be a marker for short-term breast cancer outcome prediction. Elevated serum levels of STn in ovarian cancer patients correlate with lower five-year survival rates. STn is expressed on ovarian cancer biomarkers including CA-125 (MUC16) and MUC1. It is also used as a marker to count cells in malignant nipple discharge (PND).
|
| Enzyme Assay |
Typical STn detection protocol (ELISA or immunohistochemistry): For IHC, formalin-fixed paraffin-embedded tissue sections are deparaffinized, rehydrated, and subjected to antigen retrieval. Sections are incubated with anti-STn monoclonal antibody (e.g., B72.3) at 4degC overnight, followed by HRP-conjugated secondary antibody. Signal is detected with DAB chromogen. For ELISA, STn antigen is coated on plates, blocked, incubated with primary antibody, then detected with HRP-conjugated secondary antibody and TMB substrate.
|
| Cell Assay |
STn expression on cancer cell lines can be assessed by flow cytometry: culture cancer cells (e.g., MCF-7, T47D breast cancer cells) in appropriate media. Harvest cells, wash with PBS, incubate with FITC-conjugated anti-STn antibody (1:100 dilution) on ice for 30 min. Wash, resuspend in PBS, and analyze by flow cytometry to quantify percent STn-positive cells. STn expression can also be detected by immunofluorescence staining of fixed cells.
|
| Animal Protocol |
No animal experimental protocol is provided for STn itself (it is an antigen, not a drug). For cancer vaccine studies, mice or nonhuman primates may be immunized with STn conjugated to a carrier protein (e.g., STn-KLH, keyhole limpet hemocyanin) mixed with adjuvant (e.g., Detox adjuvant). Immunization is typically given subcutaneously at weeks 0, 2, and 5, with serum collected at baseline and weekly thereafter to measure anti-STn antibody titers by ELISA.
|
| ADME/Pharmacokinetics |
Not applicable. STn/sialyl-Tn is a tumor-associated carbohydrate antigen used as a biomarker in cancer research, not a therapeutic agent administered for systemic treatment. Pharmacokinetic studies of STn itself are not conducted; however, STn-glycoconjugate vaccines have been evaluated in clinical pharmacokinetic studies in cancer patients.
|
| Toxicity/Toxicokinetics |
In clinical trials assessing the efficacy and toxicity of synthetic STn glycoconjugate vaccines in metastatic breast cancer patients, the main toxicity noted was the development of subcutaneous granulomata at injection sites, with minimal toxicity otherwise (restricted to local cutaneous reactions apart from transient nausea and vomiting following cyclophosphamide). Humanized anti-STn ADCs tested in nonhuman primates showed no toxicity even at 12 times the therapeutic dose.
|
| References | |
| Additional Infomation |
3-O-(2-Acetamido-6-O-(N-acetylneuraminyl)-2-deoxygalactosyl)serine is a non-protein L-α-amino acid composed of N-acetyl-α-neuraminic acid-(2→6)-N-acetyl-α-D-galactosamine linked to the oxygen atom at the 3-position of L-serine via an α-glycosidic bond. It is O-[N-acetyl-α-neuraminic acid-(2→6)-N-acetyl-α-D-galactosamine]-serine, a non-protein L-α-amino acid and a derivative of L-serine.
See the first source for its structure. STn/sialyl-Tn (CAS: 114661-01-7) is a research-grade compound with molecular formula C22H37N3O16 and molecular weight 599.54. Appearance: Light yellow to yellow solid powder. Purity ≥98%. It is a truncated O-glycan associated with cancer and poor prognosis. It serves as a biomarker for cancer research applications, not as a therapeutic drug. The STn antigen is widely expressed in carcinomas but only to a limited degree in normal tissue. Each product in one row, fields tab-separated. |
| Molecular Formula |
C22H37N3O16
|
|---|---|
| Molecular Weight |
599.54
|
| Exact Mass |
599.217
|
| CAS # |
114661-01-7
|
| PubChem CID |
195103
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
0
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
41
|
| Complexity |
941
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
OC(C(COC1OC(COC2(CC(O)C(NC(=O)C)C(C(C(CO)O)O)O2)C(=O)O)C(O)C(O)C1NC(=O)C)N)=O
|
| InChi Key |
RMINQIRDFIBNLE-NNRWGFCXSA-N
|
| InChi Code |
InChI=1S/C22H37N3O16/c1-7(27)24-13-10(29)3-22(21(36)37,41-18(13)15(31)11(30)4-26)39-6-12-16(32)17(33)14(25-8(2)28)20(40-12)38-5-9(23)19(34)35/h9-18,20,26,29-33H,3-6,23H2,1-2H3,(H,24,27)(H,25,28)(H,34,35)(H,36,37)/t9-,10-,11+,12+,13+,14+,15+,16-,17+,18+,20-,22+/m0/s1
|
| Chemical Name |
(2R,4S,5R,6R)-5-acetamido-2-[[(2R,3R,4R,5R,6S)-5-acetamido-6-[(2S)-2-amino-2-carboxyethoxy]-3,4-dihydroxyoxan-2-yl]methoxy]-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
|
| Synonyms |
Neu5Aca2-6GalNAc-a-Ser/Thr
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6679 mL | 8.3397 mL | 16.6795 mL | |
| 5 mM | 0.3336 mL | 1.6679 mL | 3.3359 mL | |
| 10 mM | 0.1668 mL | 0.8340 mL | 1.6679 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
